Skip to main content
Shampa Das

Professor Shampa Das
BSc, PhD

Research

Research grants

Fleming Fund Fellowship Fund

THE FLEMING FUND (UK)

February 2024 - December 2025

Expansion of assessment pharmacodynamics of flomoxef-fosfomycin and fosfomycin/amikacin combinations for neonatal sepsis using the HFIM

GARDP FOUNDATION (SWITZERLAND)

August 2022 - March 2024

Development of a new rabbit model to characterise antifungal drug resistance

FOOD AND DRUG ADMINISTATION (USA)

September 2023 - September 2025

Hit Compound to Potentiate the Activity of Amikacin for Acinetobacter baumannii (Chequerboard)

GARDP FOUNDATION (SWITZERLAND)

October 2023 - January 2024

Novel Gram-Negative Antibiotic Now (T7.2 & T7.4) (GNA NOW)

EUROPEAN COMMISSION

July 2019 - December 2025

Pharmacodynamics of Antimicrobial Combinations for Neonatal Sepsis in Low-To-Middle Income Countries

GARDP FOUNDATION (SWITZERLAND)

November 2018 - July 2021

NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (HPRU EZI)

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

April 2020 - March 2025

Assessment of the PKPD of BWC0977

BUGWORKS RESEARCH INDIA PVT. LTD. (INDIA)

September 2019 - June 2025

An evidence-based preclinical framework development antimicrobial therapeutics cystic fibrosis

CYSTIC FIBROSIS TRUST (UK)

October 2021 - September 2025

Pharmacokinetic-Pharmacodynamic assessment of BV100 in the hollow fibre infection model WP1

BIOVERSYS (SWITZERLAND)

April 2021 - February 2025

ANT3310 - Assessment of the pharmacodynamics of ANT3310 a serine beta-lactamase inhibitor

ANTABIO (FRANCE)

January 2020 - December 2020

AAI101 and Cefepime in Epithelial Lining Fluid and Plasma in Healthy Volunteers REC

ALLECRA THERAPEUTICS GMBH (GERMANY)

January 2018 - September 2022

Pharmacokinetic-Pharmacodynamic analyses of novel metallo-betalactmase inhibitors in multidrug resistant Gram negative infections

ANTABIO (FRANCE)

May 2018 - October 2019

Assessment of tebipenem in the hollow fibre

SPERO OPCO INC (USA)

August 2016 - July 2018

PK-PD analyses of cefepime and AAI101 against MDR enterobacteriaceae

ALLECRA THERAPEUTICS GMBH (GERMANY)

October 2017 - October 2018